Rare vulvar malignancies; incidence, treatment and survival in the Netherlands

Pleunis, Noortje; Schuurman, M.S.; Rossum, Michelle M. van; Bulten, Johan; Massuger, Leon F.A.G.; Hullu, Joanne A. de; Aa, M.A. van der

doi:10.1016/j.ygyno.2016.04.021

Cited by 46 publications

(28 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Australia (17)(18)(19). We also found that the incidence rate of vaginal OM had been declining, but the incidence rate of vulvar OM was stable, which was consistent with the ndings of previous studies (20,21). Although our research ruled out the probability that increased vulvar incidence was attributable to misclassi cation of vaginal cancer to vulvar cancer because of rate changes in different histological types and races for the two cancers, it remained unclear why vulvar cancer and vaginal cancer incidence rates had contrasting temporal trends.…”

Section: Discussionsupporting

confidence: 91%

Rising and Falling Trends in Incidence Rates of Vulvar and Vaginal Cancers in the United States, 2000-2016

Yue

Zhou

Pei

2020

Preprint

View full text Add to dashboard Cite

Background: Few studies focus on incidence trends in vulvar and vaginal by histological type, race, age, and region. We aimed to evaluate the temporal incidence trends and survival for the two cancers.Methods: Cases with primary vulvar or vaginal carcinoma from 2000-2016 were identified from the Surveillance, Epidemiology, and End Results 18 registries. Annual percent change (APC) and average APC (AAPC) were calculated to evaluated trends. Relative survival was estimated to compare survival outcomes.Results: Vulvar cancer incidence rates were highest among non-Hispanic whites (20.9 per 1,000,000 person-years) and in the Midwest (27.7), while vaginal cancer rates were highest among non-Hispanic blacks (8.2) and in the South (6.7). Overall, vulvar cancer rate increased 0.4% annually (AAPC, 0.4%; 95% CI, 0.1% to 0.6%), but vaginal cancer rate decreased 1.4% annually (AAPC, -1.4%; 95% CI, -2.0% to -0.5%). The increased vulvar cancer rate was only observed for squamous cell carcinoma (APC, 1.0%), while the decreased vaginal cancer rate was only observed for other malignancies (APC, -1.7%). Vulvar cancer rates increased only among whites (APC, 1.2%), but vaginal cancer rates decreased only among whites (AAPC, -1.3%) and Asians (APC, -2.7%). Vulvar cancer rates increased among patients aged 50-59 (APC, 1.1%), 60-69 (APC, 1.3%), and 70-79 (APC, 1.2%) years, while vaginal cancer rates decreased among patients aged 50-59 (APC, -1.4%) and 80 (APC, -1.4%) years or older. Overall, whites had the highest five-year relative survival for both vulvar (72.22%) and vaginal (49.03%) cancers. Conclusion: There were profound disparities in vulvar and vaginal cancer incidence rates attributable to histological type, race, age, and region. The increased vulvar cancer rates and the declined vaginal cancer rate highlights the importance of further studies to investigate the reason for the disparities.

show abstract

Section: Discussionsupporting

confidence: 91%

Rising and Falling Trends in Incidence Rates of Vulvar and Vaginal Cancers in the United States, 2000-2016

Yue

Zhou

Pei

2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Vulvar melanoma is rare, with an incidence of 0.10-0.13 per 100,000 individuals, presenting typically in post-menopausal women (3,4). In Finland, the incidence of vulvar melanoma between years 2010 and 2014 was 0.08-0.12 per 100,000 individuals (The Finnish Cancer Registry: data upon request), which is in line with other vulvar melanoma incidence studies.…”

supporting

confidence: 73%

“…Departments of 1 Dermatology, 3 Obstetrics and Gynaecology and 4 341 times higher than the risk among women without LS (p < 0.001).…”

Section: And Katri Ortementioning

confidence: 92%

Association of Vulvar Melanoma with Lichen Sclerosus

Hieta

Kurki²,

Rintala³

et al. 2019

Acta Derm Venerol

View full text Add to dashboard Cite

“…Basal cell carcinoma (BCC) is the most common form of cutaneous malignancy, accounting for about 75% of all nonmelanoma skin cancers . Vulval BCCs are uncommon, representing approximately 1% of all BCCs and 2–5% of all vulval malignancies …”

mentioning

confidence: 99%

Basal cell carcinoma of the vulva: treatment with Mohs micrographic surgery

et al. 2019

View full text Add to dashboard Cite

Vulval basal cell carcinomas (BCCs) are rare, representing < 5% of vulval malignancies and 1% of all BCCs. They often present with nonspecific symptoms and features that lead to large, poorly circumscribed and late-presenting lesions. Current and conventional treatments used to treat vulval BCC include cryotherapy, imiquimod and excision. However, recurrence rates as high as 20% have been reported with these treatments. Furthermore, there are no current clinical guidelines for their management. We present the first reported series of patients with vulval BCC treated with Mohs micrographic surgery (MMS). We report seven cases of vulval BCC treated with MMS at a tertiary referral centre over 3 years. Follow-up was performed at 3 months and up to 3 years. Our series demonstrates that there were no postoperative complications, functional sequelae or recurrences up to the 3-year follow-up. We therefore recommend that MMS should be considered in the management of vulval BCCs.

show abstract

Rare vulvar malignancies; incidence, treatment and survival in the Netherlands

Cited by 46 publications

References 18 publications

Rising and Falling Trends in Incidence Rates of Vulvar and Vaginal Cancers in the United States, 2000-2016

Rising and Falling Trends in Incidence Rates of Vulvar and Vaginal Cancers in the United States, 2000-2016

Association of Vulvar Melanoma with Lichen Sclerosus

Basal cell carcinoma of the vulva: treatment with Mohs micrographic surgery

Contact Info

Product

Resources

About